Adenovir Pharma strengthens its patents for the treatment of eye infections
Adenovir Pharma’s patent application relating to its novel compound for the treatment of the serious eye infection, epidemic keratoconjunctivitis (EKC), has been approved by the European Patent Office (EPO). Previously this patent has been approved in South Africa and is in national phase in several key markets.